HR 6393 116th Congress House Health Administrative remedies Asia China Congressional oversight Drug, alcohol, tobacco use Government information and archives Health care coverage and access Homeland security Intelligence activities, surveillance, classified information Intergovernmental relations Manufacturing Military procurement, research, weapons development Prescription drugs Public contracts and procurement

Strengthening America’s Supply Chain and National Security Act

Introduced: March 25, 2020 See on congress.gov

Everywhere this bill has been 3 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Mar 25, 2020

Referred to the Subcommittee on Trade.

Mar 25, 2020

Referred to the Committee on Ways and Means, and in addition to the Committees on Armed Services, Oversight and Reform, and Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Mar 25, 2020

Introduced in House

Plain-English summary Congressional Research Service

Strengthening America's Supply Chain and National Security Act

This bill requires the Department of Defense (DOD) and the Department of Health and Human Services (HHS) to take specified actions concerning the importation of pharmaceutical products from China and any other countries selected by DOD.

DOD must submit to Congress a classified report that addresses, among other issues, the percentage of pharmaceutical products used by DOD that are made by such countries and recommendations related to the domestic manufacturing capacity and the resiliency of the supply chain for such products. An unclassified summary of this report must be published on a DOD website.

A manufacturer of a pharmaceutical product that has received market approval must annually submit to HHS specified information about the product's active and inactive pharmaceutical ingredients, including the sources of such ingredients and the percentage of the aggregate amount of such ingredients from China and other countries selected by DOD. HHS shall provide such information to DOD.

In addition, the bill revises certain statutory tests used to determine the country of origin of a pharmaceutical product. Specifically, a pharmaceutical product shall be deemed to have the same country of origin as the product's active pharmaceutical ingredient (API). (A recent court case held that a drug manufactured in the United States using an API from India is considered a U.S.-made product for procurement purposes.)

What's happening now March 25, 2020

Referred to the Subcommittee on Trade.

Committees of jurisdiction 5